NIA's #1 overall pick for 2021 BetterLife Pharma (CSE: BETR) has announced this morning that it has applied for patent protection of its new 2-Bromo-LSD formulation TD-0148A and its use in the treatment of Major Depressive Disorder (MDD). BETR is beginning its pre-clinical work on TD-0148A in preparation for a Pre-IND Meeting with the FDA in March, which will allow BETR to file its IND to launch clinical trials of TD-0148A for the treatment of MDD later this year!
MindMed (MMEDF) had its Pre-IND Meeting with the FDA on December 14th regarding the development of LSD-assisted therapy for anxiety disorder. In the three months leading up to MMEDF's Pre-IND Meeting, its share price gained by 1,382% from $0.34 per share to a high of $5.07 per share on the day of the meeting. At MMEDF's high of $5.07 per share its market cap reached US$1.653 billion. BETR's current market cap is only US$79.69 million.
Past performance is not an indicator of future returns. NIA is not an investment advisor and does not provide investment advice. Always do your own research and make your own investment decisions. This message is not a solicitation or recommendation to buy, sell, or hold securities. NIA has received compensation from BETR of USD$50,000 cash and expects to receive an additional USD$50,000 worth of restricted BETR shares for a six-month marketing contract. NIA previously received compensation from BETR of USD$50,000 cash for a six-month marketing contract which has since expired. This message is meant for informational and educational purposes only and does not provide investment advice.